-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-08-24
This case report shows that prochlorperazine-associated neuroleptic malignant syndrome can present with the characteristic clinical syndrome despite limited laboratory abnormalities. Early medication review, neurological assessment, exclusion of competing diagnoses, and treatment with lorazepam and amantadine were associated with gradual recovery in an older patient.
-
TGF-β, Sca-1, and Mammary Cell Plasticity
2026-08-23
The reference study identifies TGF-β as a regulator of Sca-1 expression, lineage plasticity, and tumor-initiating potential in pre-neoplastic and mammary cancer cell models. Its key contribution is separating endogenous Smad2/3/4-dependent control from exogenous TGF-β-driven Sca-1 loss, providing a mechanistic framework for interpreting stem-cell markers during early tumor evolution.
-
TCAIM Control of OGDH and Mitochondrial Metabolism
2026-08-22
Wang and colleagues identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study establishes mitochondrial proteostasis as a post-translational mechanism for tuning OGDH complex activity, carbohydrate catabolism, and broader mitochondrial metabolism in cells and mice.
-
Phosbind Acrylamide: Read Phosphorylation in Context
2026-08-22
Phosbind Acrylamide enables antibody-independent protein phosphorylation analysis by converting phosphate-dependent binding into an SDS-PAGE mobility readout. This article explains how to interpret that signal responsibly, using an enterovirus 71 host-factor study to distinguish phosphorylation questions from lipid-signaling mechanisms.
-
CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness
2026-08-21
Boyle and colleagues identify a functional signaling connection between CCR7 and Notch1 in primary MMTV-PyMT mammary cancer cells. Their findings suggest that CCR7-dependent stem-like behavior requires Notch pathway activity, while also highlighting the limits of extrapolating ex vivo mouse-model data to therapeutic decisions.
-
Norepinephrine–Angiotensin II Conversion in Shock
2026-08-20
A post-hoc analysis of the ARAMIS trial estimated a clinically useful norepinephrine-to-angiotensin II conversion ratio in vasodilatory hypotension. The reported 10:1 ratio for norepinephrine bitartrate equivalents, with exploratory variation by prior angiotensin receptor blocker exposure but not baseline renin, provides a framework for vasopressor dose translation while underscoring the limits of small, single-center data.
-
SU5416 (Semaxanib) Applied Research Workflows
2026-08-20
Build reproducible VEGFR2 signaling, endothelial angiogenesis, tumor xenograft, and pulmonary vascular remodeling experiments with SU5416 (Semaxanib). This guide combines practical assay design with HGFA biomarker insights from a 2024 PAH proteomics study, while separating established product parameters from workflow recommendations.
-
Polybrene (Hexadimethrine Bromide): Mechanism & Use
2026-08-19
Polybrene, also called Hexadimethrine Bromide, is a cationic polymer used to improve viral gene delivery and selected nonviral transfection workflows. The K2701 formulation is a sterile-filtered 10 mg/mL aqueous solution in 0.9% NaCl, but exposure time, cytotoxicity, and cell type require empirical optimization.
-
HyperTrap Heparin HP Column for Stemness Research
2026-08-19
The HyperTrap Heparin HP Column translates heparin-binding selectivity into a practical workflow for enriching signaling proteins, growth factors, coagulation-related proteins, and nucleic acid-associated enzymes. Its fine-particle HyperChrom Heparin HP Agarose medium, chemical resilience, and ready-to-use format support reproducible experiments that connect biochemical fractionation with CCR7–Notch1 stemness studies.
-
Erlotinib in EGFR Signaling Workflows
2026-08-18
Erlotinib (NSC 718781) provides a reversible, nanomolar EGFR probe for connecting receptor phosphorylation with proliferation and apoptosis phenotypes. This practical guide shows how to build, optimize, and interpret cell-based and translational assays while distinguishing EGFR blockade from SCUBE3-directed therapy.
-
DMXAA (Vadimezan): Mechanism and Research Use
2026-08-18
DMXAA, also known as Vadimezan, is a vascular disrupting compound investigated for tumor endothelial apoptosis, angiogenesis inhibition, and cancer biology research. Its preclinical profile spans DT-diaphorase inhibition, VEGFR2-related signaling effects, and STING-agonist activity in a nuclear-targeted nanorod formulation.
-
Z-VEID-FMK: Caspase-6 Inhibition in Apoptosis
2026-08-17
Z-VEID-FMK provides a practical way to test whether caspase-6 is causally involved in apoptosis rather than merely associated with it. This workflow also translates a recent SVA–DDX23 host-virus study into a focused assay strategy while clarifying where caspase-6 inhibition should not be overinterpreted.
-
U0126 in Mechanobiology: MEK1/2 Assay Workflows
2026-08-17
U0126 provides a practical way to test whether stiffness-dependent phenotypes require MEK1/2 activity, extending dentinogenesis studies beyond descriptive pathway mapping. This workflow combines controlled PDMS substrates, time-resolved ERK readouts, mineralization assays, and troubleshooting guidance for reproducible MAPK/ERK pathway inhibition.
-
PreScission Protease for Native Protein Recovery
2026-08-16
PreScission Protease enables sequence-specific fusion protein tag cleavage at low temperature, supporting recovery of tag-free recombinant proteins. This article connects HRV 3C protease design with assay decisions inspired by research on dKeap1–lamin-dependent nuclear architecture.
-
Triterpene Prodrug for Targeted OSCC Chemotherapy
2026-08-15
The reference study develops a carrier-free, self-assembled prodrug that combines glycyrrhetinic acid and ginsenoside Rh2 through a ROS-responsive thioketal design for oral squamous cell carcinoma therapy. Its central innovation is a self-boosting mechanism in which tumor-associated oxidative stress releases the active agents, while glycyrrhetinic acid further increases ROS to amplify drug release and apoptotic damage.